Claradele Pharmaceuticals
Pre-clinicalClaradele Pharmaceuticals is a pre-clinical stage biotechnology company dedicated to developing effective and non-toxic cancer therapeutics. Its core asset is 15dPMJ2, a patented small molecule that uniquely induces cytotoxic ER stress in tumor cells while stimulating an anti-tumor immune response, demonstrating 76% tumor growth reduction in pre-clinical models. The company is initially targeting melanoma in US and European markets, with potential expansion into colon and lung cancers, leveraging its founder's deep academic expertise in oncology research.
Private Company
Funding information not available
AI Company Overview
Claradele Pharmaceuticals is a pre-clinical stage biotechnology company dedicated to developing effective and non-toxic cancer therapeutics. Its core asset is 15dPMJ2, a patented small molecule that uniquely induces cytotoxic ER stress in tumor cells while stimulating an anti-tumor immune response, demonstrating 76% tumor growth reduction in pre-clinical models. The company is initially targeting melanoma in US and European markets, with potential expansion into colon and lung cancers, leveraging its founder's deep academic expertise in oncology research.
Technology Platform
A novel small molecule drug class (exemplified by 15dPMJ2) designed to have dual cytotoxic and immunostimulatory activity, selectively inducing endoplasmic reticulum (ER) stress in tumor cells to kill them and stimulate a tumor-specific immune memory response.
Opportunities
Risk Factors
Competitive Landscape
Competes against large pharma immunotherapies (e.g., Merck's Keytruda) and targeted therapies in melanoma, plus numerous biotech novel modalities. Differentiation is claimed via a single small molecule with combined direct tumor killing and immune stimulation, aiming for selectivity and lower cost than biologics.